With respect to AD, elevation in CSF NfL levels is even more pronounced in FTD [240], in which this biomarker can exert a very relevant clinical application in the differential diagnosis with non-neurodegenerative disease mimics. The gene discussed is NEFL; the disease is Alzheimer disease.